Bepreve
| Bepreve | |
|---|---|
| DOSAGE | 1 gtt BID |
| GENERIC | bepotastine besilate 1.5% |
| SIZE | 5mL, 10mL |
| INDICATIONS | BEPREVE® (bepotastine besilate ophthalmic solution) 1.5% is a histamine H1 receptor antagonist indicated for the treatment of itching associated with signs and symptoms of allergic conjunctivitis. |
| MECHANISM OF ACTION | Combo Mast Cell Stabilizer / Anti H1 |
| MICROBIOLOGY | Nedocromil sodium inhibits the release of mediators from cells involved in hypersensitivity reactions. Decreased chemotaxis and decreased activation of eosinophils have also been demonstrated. Also inhibits histamine release from a population of mast cells having been defined as belonging to the mucosal sub type and inhibits beta-glucuronidase release from macrophages. |
| CONTRAINDICATIONS & WARNINGS | BEPREVE is contraindicated in patients with a history of hypersensitivity reactions to bepotastine or any of the other ingredients |
| PEDIATRIC USE | Safety and efficacy of BEPREVE (bepotastine besilate ophthalmic solution) 1.5% have not been established in pediatric patients under 2 years of age. |
| Efficacy in pediatric patients under 10 years of age was extrapolated from clinical trials conducted in pediatric patients greater than 10 years of age and from adults. | |
| PREGNANCY | Category C: There are no available human data for the use of BEPREVE during pregnancy to inform any drug-associated risks .Oral administration of bepotastine besilate to pregnant rats or rabbits during organogenesis or during the pre/postnatal period did not produce adverse embryofetal or offspring effects at clinically relevant systemic exposures. Maternal toxicity was observed in the rabbits at the lowest dose administered |
| NOTE | BAK .005%. Remove contact lenses prior 10mins prior to instillation of BEPREVE. |